Lawrence Picciano - Helius Medical Quality Engineering
HSDT Stock | USD 0.42 0.02 5.00% |
Insider
Lawrence Picciano is Quality Engineering of Helius Medical Technologies
Address | 642 Newtown Yardley Road, Newtown, PA, United States, 18940 |
Phone | 215 944 6100 |
Web | https://heliusmedical.com |
Helius Medical Management Efficiency
The company has return on total asset (ROA) of (1.1256) % which means that it has lost $1.1256 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.598) %, meaning that it created substantial loss on money invested by shareholders. Helius Medical's management efficiency ratios could be used to measure how well Helius Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.09 in 2025. Return On Capital Employed is likely to drop to -2.02 in 2025. At this time, Helius Medical's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 384.8 K in 2025, whereas Total Current Liabilities is likely to drop slightly above 1.6 M in 2025.Helius Medical Technologies currently holds 57 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Helius Medical Techn has a current ratio of 2.79, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Helius Medical's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | INSIDER Age | ||
Kirk Huntsman | Vivos Therapeutics | 66 | |
Michael Goodman | STRATA Skin Sciences | N/A | |
Jennifer Ernst | Tivic Health Systems | 57 | |
Victoria Vezina | Rapid Micro Biosystems | 56 | |
John Liu | Sight Sciences | N/A | |
Mark Knudson | ReShape Lifesciences | 76 | |
Danielle Watson | Heart Test Laboratories | 43 | |
Paul Badawi | Sight Sciences | 49 | |
Julie Gannon | Vivos Therapeutics | N/A | |
Sam Park | Sight Sciences | 63 | |
Jeremy Hayden | Sight Sciences | 54 | |
Darrell Rigel | STRATA Skin Sciences | 73 | |
John Wilson | Rapid Micro Biosystems | 57 | |
David Meyer | Aurora Spine | N/A | |
JD MBA | SINTX Technologies | 60 | |
Christopher Lesovitz | STRATA Skin Sciences | 41 | |
Mark MD | Bluejay Diagnostics | N/A | |
Kevin Vance | Bluejay Diagnostics | 67 | |
Rob Scott | Nuwellis | N/A | |
MBA BS | Sight Sciences | N/A | |
RaeAnn Byrnes | Vivos Therapeutics | N/A |
Management Performance
Return On Equity | -2.6 | ||||
Return On Asset | -1.13 |
Helius Medical Techn Leadership Team
Elected by the shareholders, the Helius Medical's board of directors comprises two types of representatives: Helius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Helius. The board's role is to monitor Helius Medical's management team and ensure that shareholders' interests are well served. Helius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Helius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Treasurer, CFO | ||
Lawrence Picciano, Quality Engineering | ||
Antonella MD, Chief Officer | ||
Jeffrey CPA, Treasurer, CFO | ||
Dane Andreeff, CEO President | ||
Brian Bapty, VP of Strategy and Bus. Devel. |
Helius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Helius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -2.6 | ||||
Return On Asset | -1.13 | ||||
Operating Margin | (79.80) % | ||||
Current Valuation | (1.15 M) | ||||
Shares Outstanding | 5.67 M | ||||
Shares Owned By Insiders | 0.52 % | ||||
Shares Owned By Institutions | 6.63 % | ||||
Number Of Shares Shorted | 55.52 K | ||||
Price To Earning | (13.85) X | ||||
Price To Book | 0.60 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Helius Stock Analysis
When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.